Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...
Daiichi Sankyo press release ( OTCPK:DSKYF ): 9M GAAP EPS of ¥45.19. Revenue of ¥948.28B (+16.9% Y/Y). For further details see: Daiichi Sankyo GAAP EPS of ¥45.19, revenue of ¥948.28B
Summary As a leader in various therapeutic areas, the company's total revenue was $7,042 million in the third quarter of 2022, up 12.5% quarter-on-quarter. Gilead will be required to make royalties of 3% on future sales of Biktarvy and bictegravir-containing medicines up to the 4th quar...
Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) submitted an application to the regulatory authorities in Japan seeking approval of its mRNA COVID-19 vaccine DS-5670 as a booster shot. The Japanese drugmaker said the application was backed by data from a phase 1/2/3 tri...
Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...
Summary FDA and EU approved, the joint therapy Enhertu is set to become a blockbuster. The therapy targets HER-2 cancers and is already expanding indications beyond breast cancer. With this successful antibody-drug conjugate, the entire sub-industry is now seeing renewed momentum he...
Japanese pharmaceutical giant Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) on Wednesday said Europe's drug regulator had validated a change to its application for lung cancer treatment Enhertu. The European Medicines Agency (EMA) validated a Type II variation application for Enhertu...
Summary VPL's portfolio is highly diversified, invests significantly in sectors with high growth potential, has a low expense ratio, and is trading at a marginal discount. Though VPL's current yield is not excessively high, it seems to be sustainable and the fund generates a high enough...
Kite Pharma, a Gilead Company ( NASDAQ: GILD ), and Daiichi Sankyo Co., Ltd. ( OTCPK:DSNKY ) jointly announced the revision of their 2017 partnership pact , which gave Daiichi Sankyo exclusive rights to develop, manufacture and commercialize Yescarta in Japan. Kite was ac...
Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) said its mRNA-based COVID-19 vaccine DS-5670 met the main goal in a booster vaccination trial. The Japanese company said the booster vaccination trial included ~5K Japanese healthy adult and elderly people who had compl...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...